News Releases

January 4, 2022
Company Actively Dosing Patients for Phase 2 Pivotal Efficacy Study for MELT-300; Full Enrollment Followed by Readout on Topline Data Expected by End of Second Quarter of 2022 NASHVILLE, Tenn.--(BUSINESS WIRE)--Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing

Search